Research programme: protein-protein interaction modulators - SYGNIS Pharma AG
Latest Information Update: 16 Jul 2016
At a glance
- Originator SYGNIS Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- Available For Licensing Yes - Unspecified
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Germany
- 15 Jan 2013 Early research in undefined indication in Germany (unspecified route)
- 15 Jan 2013 SYGNIS Pharma's protein-protein interaction screening technology is available for licensing in Europe and the USA as of 15 Jan 2013. http://www.sygnis.de/